However, TGF-β treatment significantly reduced the BrdU-positive cell fraction in DDB2-overexpressing CP70 cells, indicating that DDB2 is able to sensitize ovarian cancer cells to the growth inhibitory effect of TGF-β. This evidence concerns the gene TGFB1 and ovarian carcinoma.